Trellus Health PLC (GB:TRLS) has released an update.
Trellus Health PLC has reported promising early results from its B2B2C agreement with a major US health plan for managing IBD, despite slower than anticipated enrollment numbers. The company has also diversified its revenue streams by signing content licensing agreements with two large pharmaceutical companies, leveraging its proprietary resilience-based approach. With a focus on cash management, Trellus Health has extended its cash runway into late Q3 2025 and continues to seek further commercial partnerships.
For further insights into GB:TRLS stock, check out TipRanks’ Stock Analysis page.
